Infectious diseases focus of research for vaccines

Infectious diseases are still a large cause of death around the world even though scientists have made major advancements in treating these diseases since the 1920s. Fierce Biotech states that there are currently 395 currently in the late stage of development, which means they are being reviewed by the FDA. Doctors are currently seeing that many of the diseases which currently have vaccines and medications are mutating and "Super Bugs" are forming. These drug-resistant viruses are increasing. In addition to working on those medicines and vaccines, scientists are taking a particular interest in diseases affecting third world countries including developing world, such as the Ebola virus, dengue fever, yellow fever, typhoid and cholera.

Share this article with your social network, just click below to share now!

Share |

Cloud Services for Biopharma R&D

Fierce Biotech reports today that Biopharma research and development organzations need to be mindful when purchasing a cloud computing service.

Cloud computing--a data-crunching force multiplier that allows companies to draw on resources across the Internet, either on the fly or as a dedicated service--is potentially disruptive to companies because it changes the dynamic of who owns the capital assets, turning traditional IT infrastructure models on their heads.

Be cautious, but be open-minded," says Rick Franckowiak, director for systems engineering at the Pharmaceutical Research & Development IT organization of Johnson & Johnson. Likewise: "Be careful," says Brian Boruff, vice president for cloud computing at systems integration consultancy Computer Sciences Corp., a cloud service provider.

Read more: Fierce Cloud Services for Biopharma R&D

Share this article with your social network, just click below to share now!

Share |